Literature DB >> 21983870

Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes.

Yu Zhen1, Lina Sun, He Liu, Kaizhong Duan, Chun Zeng, Lianjun Zhang, Di Jin, Jianxia Peng, Wenjun Ding, Yong Zhao.   

Abstract

Complications arising from abnormal immune responses are the major causes of mortality and morbidity in diabetic patients. CD4+CD25+T regulatory cells (Tregs) play pivotal roles in controlling immune homeostasis, immunity and tolerance. The effect of hyperglycemia on CD4+CD25+Tregs has not yet been addressed. Here we used streptozotocin (STZ)-induced diabetic mice to study the effects of long-term hyperglycemia on CD4+CD25+Tregs in vivo. Four months after the onset of diabetes, the frequency of CD4+CD25+Foxp3+ T regulatory cells was significantly elevated in the spleen, peripheral blood lymphocytes (PBLs), peripheral lymph nodes (pLNs) and mesenteric LNs (mLNs). CD4+CD25+Tregs obtained from mice with diabetes displayed defective immunosuppressive functions and an activated/memory phenotype. Insulin administration rescued these changes in the CD4+CD25+ Tregs of diabetic mice. The percentage of thymic CD4+CD25+ naturally occurring Tregs (nTregs) and peripheral CD4+Helios+Foxp3+ nTregs were markedly enhanced in diabetic mice, indicating that thymic output contributed to the increased frequency of peripheral CD4+CD25+Tregs in diabetic mice. In an in vitro assay in which Tregs were induced from CD4+CD25- T cells by transforming growth factor (TGF)-β, high glucose enhanced the efficiency of CD4+CD25+Foxp3+ inducible Tregs (iTregs) induction. In addition, CD4+CD25- T cells from diabetic mice were more susceptible to CD4+CD25+Foxp3+ iTreg differentiation than those cells from control mice. These data, together with the enhanced frequency of CD4+Helios-Foxp3+ iTregs in the periphery of mice with diabetes, indicate that enhanced CD4+CD25+Foxp3+ iTreg induction also contributes to a peripheral increase iCD4+CD25+Tregs in diabetic mice. Our data show that hyperglycemia may alter the frequency of CD4+CD25+Foxp3+ Tregs in mice, which may result in late-state immune dysfunction in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983870      PMCID: PMC4002930          DOI: 10.1038/cmi.2011.37

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  45 in total

1.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors.

Authors:  Anna Morena D'Alise; Vincent Auyeung; Markus Feuerer; Junko Nishio; Jason Fontenot; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

2.  Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls.

Authors:  Sanja Glisic; Sarah Ehlenbach; Parthav Jailwala; Jill Waukau; Srikanta Jana; Soumitra Ghosh
Journal:  Cell Tissue Res       Date:  2010-02-09       Impact factor: 5.249

3.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

4.  Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions.

Authors:  A K Daoud; M A Tayyar; I M Fouda; N Abu Harfeil
Journal:  J Immunotoxicol       Date:  2009-03       Impact factor: 3.000

5.  Diabetes-induced alteration of F4/80+ macrophages: a study in mice with streptozotocin-induced diabetes for a long term.

Authors:  Haixia Ma; Guangwei Liu; Wenjun Ding; You Wu; Lu Cai; Yong Zhao
Journal:  J Mol Med (Berl)       Date:  2008-01-30       Impact factor: 4.599

6.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Authors:  Qizhi Tang; Jason Y Adams; Cristina Penaranda; Kristin Melli; Eliane Piaggio; Evridiki Sgouroudis; Ciriaco A Piccirillo; Benoit L Salomon; Jeffrey A Bluestone
Journal:  Immunity       Date:  2008-05-08       Impact factor: 31.745

Review 7.  Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?

Authors:  Maria A Curotto de Lafaille; Juan J Lafaille
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

8.  Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.

Authors:  Sylvaine You; Lynn Poulton; Steve Cobbold; Chih-Pin Liu; Michael Rosenzweig; Douglas Ringler; Wen-Hui Lee; Berta Segovia; Jean-François Bach; Herman Waldmann; Lucienne Chatenoud
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

9.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

10.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.

Authors:  Xuyu Zhou; Samantha L Bailey-Bucktrout; Lukas T Jeker; Cristina Penaranda; Marc Martínez-Llordella; Meredith Ashby; Maki Nakayama; Wendy Rosenthal; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-07-26       Impact factor: 25.606

View more
  11 in total

1.  Impact of hyperglycemia on autoimmune pancreatitis and regulatory T-cells.

Authors:  Franz-Tassilo Müller-Graff; Brit Fitzner; Robert Jaster; Brigitte Vollmar; Dietmar Zechner
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

2.  Differential control of Helios(+/-) Treg development by monocyte subsets through disparate inflammatory cytokines.

Authors:  Hui Zhong; Karina Yazdanbakhsh
Journal:  Blood       Date:  2013-01-30       Impact factor: 22.113

3.  Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.

Authors:  Lan He; Priscilla T Y Law; Chun Kwok Wong; Juliana C N Chan; Paul K S Chan
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

Review 4.  Regulatory role of natural killer T cells in diabetes.

Authors:  Celine Tard; Ophelie Rouxel; Agnes Lehuen
Journal:  Biomed J       Date:  2016-03-10       Impact factor: 4.910

Review 5.  Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?

Authors:  Anna Grohová; Klára Dáňová; Radek Špíšek; Lenka Palová-Jelínková
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

6.  Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity.

Authors:  Peng Zhang; Chun-Lin Yang; Tong Du; Yu-Dong Liu; Meng-Ru Ge; Heng Li; Ru-Tao Liu; Cong-Cong Wang; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2021-10-26       Impact factor: 8.322

Review 7.  Inflammation in diabetic nephropathy.

Authors:  Andy K H Lim; Gregory H Tesch
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

8.  Indirubin Increases CD4+CD25+Foxp3+ Regulatory T Cells to Prevent Immune Thrombocytopenia in Mice.

Authors:  Aijun Zhang; Bin Ning; Nianzheng Sun; Jianlu Wei; Xiuli Ju
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

9.  Hepatic immunophenotyping for streptozotocin-induced hyperglycemia in mice.

Authors:  Young-Sun Lee; Hyuk Soo Eun; So Yeon Kim; Jong-Min Jeong; Wonhyo Seo; Jin-Seok Byun; Won-Il Jeong; Hyon-Seung Yi
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

10.  Polysaccharides from Chinese Herbal Lycium barbarum Induced Systemic and Local Immune Responses in H22 Tumor-Bearing Mice.

Authors:  Xiangliang Deng; Shuang Luo; Xia Luo; Minghua Hu; Fangli Ma; Yuanyuan Wang; Xiaoping Lai; Lian Zhou
Journal:  J Immunol Res       Date:  2018-06-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.